

Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment

Neurol Neuroimmunol Neuroinflamm 2020;7:e733. doi:10.1212/NXI.0000000000000733

In the article “Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment” by Muñoz-Lopetegi et al.,¹ published online March 2, 2020, the y-axis label for figure 5’s right graph should be “CSF anti-GAD65 concentration (IU/mL).” The editorial office regrets the error.

Reference

1. Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e696. doi: 10.1212/NXI.0000000000000696.

Neurology® Neuroimmunology & Neuroinflammation

Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment

Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000733

This information is current as of April 15, 2020

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/7/4/e733.full.html
References	This article cites 1 articles, 1 of which you can access for free at: http://nn.neurology.org/content/7/4/e733.full.html##ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2020 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.

